Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Pediatric Blood & Cancer

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.27094PMID 29697184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Visfatin mediates doxorubicin resistance in human non–small‐cell lung cancer via Akt‐mediated up‐regulation of ABCC1

  2017cited by this paper
• Hydrazinyldiene-chroman-2,4-diones in inducing growth arrest and apoptosis in breast cancer cells: Synergism with doxorubicin and correlation with physicochemical properties

  2017cited by this paper
• Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.

  2017cited by this paper
• Anaplastic large cell lymphoma in paediatric and young adult patients

  2016cited by this paper
• Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management

  2016cited by this paper
• Pathobiology ofALK anaplastic large-cell lymphoma

  2016cited by this paper
• Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling

  2016cited by this paper
• Genetics of anaplastic large cell lymphoma

  2016cited by this paper
• Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism

  2016cited by this paper
• An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

  2016cited by this paper
• The biology and management of systemic anaplastic large cell lymphoma.

  2015cited by this paper
• Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma

  2015cited by this paper
• limma powers differential expression analyses for RNA-sequencing and microarray studies

  2015cited by this paper
• Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma

  2015cited by this paper
• Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo‐HSCT with reduced intensity conditioning regimen

  2015cited by this paper
• Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.

  2014cited by this paper
• A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation

  2014cited by this paper
• Anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease

  2014cited by this paper
• STRING v10: protein–protein interaction networks, integrated over the tree of life

  2014cited by this paper
• Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group

  2014cited by this paper
• Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

  2013cited by this paper
• The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update

  2013cited by this paper
• Identification of C/EBPβ Target Genes in ALK+ Anaplastic Large Cell Lymphoma (ALCL) by Gene Expression Profiling and Chromatin Immunoprecipitation

  2013cited by this paper
• Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

  2013cited by this paper
• Differential expression of aurora-A kinase in T-cell lymphomas

  2013cited by this paper
• MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

  2013cited by this paper
• Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma

  2013cited by this paper
• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

  2012cited by this paper
• Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.

  2011cited by this paper
• Anaplastic large cell lymphoma: twenty-five years of discovery.

  2011cited by this paper
• Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas.

  2011cited by this paper
• Doxorubicin pathways: pharmacodynamics and adverse effects

  2011cited by this paper
• Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.

  2010cited by this paper
• Studies of Phosphoproteomic Changes Induced by Nucleophosmin-Anaplastic Lymphoma Kinase (ALK) Highlight Deregulation of Tumor Necrosis Factor (TNF)/Fas/TNF-related Apoptosis-induced Ligand Signaling Pathway in ALK-positive Anaplastic Large Cell Lymphoma*

  2010cited by this paper
• Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

  2010cited by this paper
• Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

  2010cited by this paper
• Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

  2009cited by this paper
• Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.

  2009cited by this paper
• Upregulation of the CDC25A phosphatase downstream of the NPM/ALK oncogene participates in anaplastic large cell lymphoma enhanced proliferation

  2009cited by this paper
• The expression of granulysin in systemic anaplastic large cell lymphoma in childhood.

  2009cited by this paper
• Anaplastic lymphoma kinase: signalling in development and disease

  2009cited by this paper
• A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

  2009cited by this paper
• Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma

  2009cited by this paper
• Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma

  2009cited by this paper
• Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology.

  2009cited by this paper
• Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

  2008cited by this paper
• STAT3-Mediated Up-Regulation of BLIMP1 Is Coordinated with BCL6 Down-Regulation to Control Human Plasma Cell Differentiation1

  2008cited by this paper
• Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

  2007cited by this paper
• Pathobiology of ALK+ anaplastic large-cell lymphoma.

  2007cited by this paper
• Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.

  2007cited by this paper
• CD30 Activates Both the Canonical and Alternative NF-κB Pathways in Anaplastic Large Cell Lymphoma Cells*

  2007cited by this paper
• The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.

  2006cited by this paper
• Reappraisal of BCL3 as a Molecular Marker of Anaplastic Large Cell Lymphoma

  2005cited by this paper
• Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.

  2005cited by this paper
• Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms

  2004cited by this paper
• cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

  2003cited by this paper
• The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.

  2002cited by this paper
• Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens

  2002cited by this paper
• Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

  2001cited by this paper
• Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.

  2000cited by this paper
• Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology.

  2000cited by this paper
• BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.

  2000cited by this paper
• ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

  1998cited by this paper
• Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood.

  1997cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma.

  1994cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Pediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood.

  1994cited by this paper
• Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood.

  1993cited by this paper
• A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis.

  1989cited by this paper
• A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki‐1 lymphoma')

  1989cited by this paper
• The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

  1985cited by this paper

• SOHO State of the Art Updates and Next Questions | Update on Tailoring Therapy in T Cell Lymphomas.

  2025cites this paper
• Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

  2024cites this paper
• Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability

  2023cites this paper
• Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma

  2021cites this paper
• Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALK + ALCL

  2021cites this paper
• The Challenges of Crizotinib Treatment in a Child With Anaplastic Large Cell Lymphoma.

  2021cites this paper
• Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target

  2020cites this paper
• From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK+

  2019cites this paper